



Published in final edited form as:

*Mol Neurobiol.* 2009 February ; 39(1): 50–61. doi:10.1007/s12035-009-8051-6.

## Cellular and Molecular Neurobiology of Brain Preconditioning

**Jean Lud Cadet and Irina N. Krasnova**

*Molecular Neuropsychiatry Research Branch, Intramural Research Program, NIDA/NIH/DHHS 251 Bayview Boulevard, Baltimore, MD 21224*

### Abstract

The tolerant brain which is a consequence of adaptation to repeated non-lethal insults is accompanied by the up-regulation of protective mechanisms and the down-regulation of pro-degenerative pathways. During the past 20 years, evidence has accumulated to suggest that protective mechanisms include increased production of chaperones, trophic factors, and other anti-apoptotic proteins. In contrast, preconditioning can cause substantial dampening of the organism's metabolic state and decreased expression of pro-apoptotic proteins. Recent microarray analyses have also helped to document a role of several molecular pathways in the induction of the brain refractory state. The present review highlights some of these findings and suggests that a better understanding of these mechanisms will inform treatment of a number of neuropsychiatric disorders.

### Introduction

Effective neuroprotection against neurodegenerative insults is one of the most interesting and clinically important goals of research in neurology and psychiatry [1]. One of the approaches that have received a great deal of attention is the phenomenon whereby exposure to sub-toxic or sub-lethal doses of toxins can result in protection against larger doses of the same toxins and other toxic events. The present state of affairs is different from ideas promulgated about three decades ago when it was thought that exposure to successive brief periods of ischemia had a cumulative effect leading to tissue necrosis and organ dysfunction [2]. These ideas were put to rest when it was demonstrated that animals exposed to four 5-minute long occlusions followed by 40 minutes occlusion showed smaller infarct size whereas animals exposed to the same pre-treatment paradigm but to 3 hours of occlusion did not show protection [3]. Experiments in canine models of myocardial ischemia showed that cardiac myocytes exposed to 10 minutes of ischemia would sustain loss of intracellular adenosine triphosphate (ATP) and adenine nucleotide depletion whereas cells exposed to a further 10-minutes ischemic insult after an intervening 20-minutes of reperfusion did not experience further ATP loss [4]. These findings led to suggestions that multiple brief ischemic episodes might provide some degree of protection against subsequent prolonged ischemic insults [3,4]. This type of pretreatment-induced protection is not limited to cardiac cells because other tissues including skeletal muscle [5], liver [6,7] and the brain [8] experience a similar phenomenon. This process has been called preconditioning [9].

Brain preconditioning is a phenomenon in which the brain protects itself against future injury by adapting to low doses of noxious insults [10]. Groups of investigators from diverse fields have used different approaches to show that stimuli such as anesthetic agents, hypothermia and hyperthermia, hypoxia/ischemia, as well as low doses of certain toxins can promote

---

Address correspondence to: Jean Lud Cadet, M.D., Chief, Molecular Neuropsychiatry Research Branch, Intramural Research Program, NIDA/NIH/DHHS, 251 Bayview Boulevard, Baltimore, MD 21224, Phone:(443) 740-2656, Fax: (443) 740-2856, E-mail: E-mail: jcadet@intra.nida.nih.gov.

preconditioning-dependent protective responses. Elucidation of the basic mechanisms underlying these responses promises to significantly influence therapeutic approaches that will impact the course of a number of neurologic disorders. These include the acute and chronic treatment of cerebrovascular accidents and, possibly, the chronic treatment of neurological disorders that are characterized by chronic progressive courses. Thus, the purpose of this review is to provide a brief summary of the models of brain preconditioning and to discuss the cellular and molecular bases of the tolerant brain. Although there is evidence that postconditioning might also provide protection against models of focal ischemia [11], discussion of this phenomenon is beyond the scope of the present paper.

## Models of Neuronal Preconditioning

Cerebrovascular accidents are among the leading causes of morbidity and mortality in the world [12]. Strokes are subdivided into ischemic and hemorrhagic strokes, with ischemic strokes representing about 85% of all cases [13]. Ischemic strokes are the consequences of transient or permanent thrombo-embolic events and of systemic hypoperfusion which cause inefficient delivery or marked decreases in the delivery of oxygen and glucose to the brain [14,15]. These ischemic events can result from partial or complete vascular occlusions and can cause variable degrees of neuroanatomical damage and associated neurological deficits. The decrease in blood flow and associated diminution of nutrients delivered to the brain is known to cause activation of cellular and molecular processes that cause neuronal death via excitotoxicity, pH and ionic imbalances, oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunctions, as well as pro-toxic inflammatory responses [14–16]. Even though some of these pathways are being investigated actively, much remains to be done in order to develop therapeutic approaches that might tamper the course of ischemia-induced injuries. Because ischemia-induced pathobiological processes appear to have complex and, sometimes, divergent time courses that can occur within minutes, hours, and/or days, specific time-dependent therapeutic manipulations might be needed to address the damage caused to the various cell types that are affected by hypoxic/ischemic injuries [17,18]. Thus, specific interventions would have to counter the excitotoxic effects of severe restriction of blood flow that causes necrotic cell death within the central core of a stroke while other approaches would have to prevent ischemic effects in the penumbra [14]. Still other avenues of treatment would need to focus on remedying the effects of a stroke on individual cells that might be impacted by more delayed inflammatory processes [19]. These issues are important because, although controversial, it has been suggested that patients who experienced prior transient ischemic attacks might suffer from less severe strokes later on [20–22].

The accumulated evidence generated from models of cardiac preconditioning is influencing information-driven approaches to the treatment of myocardial injury [23]. Although research in brain preconditioning is lagging, somewhat, behind similar research in cardiology, it is possible that similar approaches might prove fruitful in the treatment of strokes. Indeed, as in cardiac preconditioning, the development of a tolerant brain appears to result from the activation of endogenous mechanisms of protection against brain injuries [10]. The mechanisms involved in this type of tolerance to ischemic brain injuries have been investigated using both in vivo and in vitro models. These are discussed below.

### Gerbil models

About three decades ago, Kirino [24] discussed a model in which Mongolian gerbils were subjected to bilateral carotid occlusion for 5 min followed by processing of their brains for light and electron microscopy. The author reported that there occurred rapid ischemic changes in the CA4 region, with development of slower abnormalities in the CA2 area and even still slower changes in the CA1 region [24]. Using that model, Kitagawa and others [25] showed that exposure to 2 min of ischemia caused depletion of high-energy phosphate compounds and

perturbation of protein synthesis without any evidence of neuronal death. In addition, they found that single episodes of 2-min ischemia were able to provide protection against cell death caused by 5 min ischemic events performed 1 or 2 days after the pretreatment. Moreover, two 2-min ischemic pretreatments performed one day apart provided complete protection against cell death induced by 5 minutes of ischemia [25]. Kato et al. [26] also showed that preconditioning with 2 min of ischemia prevented damage to the hippocampal CA1 area following 3 min of ischemia induced 3 days later. In addition, Miyashita et al. [27] reported that pretreatment with unilateral occlusion of the middle cerebral artery (MCA) could induce ischemic tolerance in the hippocampal CA1 neurones of gerbils [27]. Moreover, Ohtsuki et al. [28] showed that a 2-min preconditioning ischemia also protected gerbil hippocampal neurons against damage caused by a 3.5 min ischemia performed 3 days later. Because previous investigators had focused their attention on younger animals and because most ischemic strokes occur in older individuals, Dowden and Corbett [29] used 18- to 20-month-old gerbils to test if they could observe preconditioning-induced protection in these animals. They found that two 1.5-minute episodes of global ischemia separated by 24 hours protected animals who underwent a 5-minute occlusion of both carotid arteries 72 hours later. They also reported normal microtubule-associated protein-2 expression in the hippocampal CA1 region of preconditioned animals in contrast to the complete loss of microtubule-associated protein-2 staining observed in ischemic animals. Kitagawa et al. [30] used the gerbil model to investigate if neurons adjacent to ischemic lesions would acquire tolerance to subsequent ischemic insults. They reported that there was significant attenuation of structural damage in the hippocampus of these animals, a phenomenon which lasted up to two weeks after the initial preconditioning stimulus.

## Rats

Liu et al. [31] used rats to test if preconditioning with sub-lethal ischemia could protect against neuronal death caused by subsequent lethal ischemic insults. They showed that forebrain ischemia for 3 min was able to protect against hippocampal CA1 neuronal damage caused by 6 and 8 min of ischemia but not against damage caused by 10 min of ischemia [31]. Simon et al. [32] also showed that two brief periods of global cerebral ischemia, separated by 24 h, which did not cause significant cell death in the brain was able to significantly reduce the size of an infarct caused by permanent MCA occlusion. Glazier et al. [33] also investigated the possibility that a brief period of focal ischemia could cause ischemic tolerance in the rat brain. They induced focal ischemia via the MCA occlusion for 20 min. Following a 24 hours of recovery, the authors subjected the animals to a 10-min of forebrain ischemia and processed the brain for histopathological examination 3–4 days after surgery. They found substantial degrees of neuronal death in the cerebral cortex, striatum, hippocampus, and thalamus [33]. Matsushima and Hakim [34] also reported that global ischemia can provide substantial protection against strokes caused by MCA occlusion in the rat brain. Moreover, Belayev et al. [35] also investigated whether transient unilateral MCA occlusion for 2 hours could induce bilateral ischemic tolerance to hippocampal damage caused by bilateral two-vessel occlusion (2-VO). They reported that animals subjected to MCA occlusion and the 2-VO procedure were protected against 2-VO-induced cell death in the hippocampus. In another very interesting study, Perez-Pinzon et al. [36] assessed the possibility that ischemic preconditioning done only 30 min before a lethal insult could still offer protection against histological damage in the rat brain. In that study, the conditioning ischemic insult lasted 2 min. After only 30 min of reperfusion, the rats were subjected to 10-min of ischemia. There were significant degrees of protection in the hippocampal CA1 subfield and in the cortex [36].

## In vitro models

Cell culture systems have also been used extensively to investigate the effects of preconditioning. The model of combined oxygen and glucose deprivation (OGD) that

recapitulates the cascades of changes that occur during ischemia-induced injuries in the mammalian brain [37,38] has been used extensively to investigate potential bases of preconditioning-induced neuroprotection. In that model, transient deprivation of rodent cortical cell cultures of both oxygen and glucose causes neuronal swelling, followed by severe neuronal degeneration over a period of several hours even when the cells were returned to normal media [37]. Acute and delayed injuries were inhibited by combined removal of extracellular  $\text{Ca}^{2+}$  in conjunction with  $\text{Na}^+$  or  $\text{Cl}^-$  substitution. The toxic effects of OGD appear to be mediated by excitotoxic damage because it causes a large increase in the levels of extracellular glutamate and because N-methyl-D-aspartate (NMDA) receptor antagonists provided protection against both the early and the late damage caused by OGD. Bruer et al. [39] used the OGD model to study the effects of preconditioning in vitro. They found that cellular damage was significantly reduced in cells pre-exposed to 1.5 hours of OGD with an intervening 48–72 hours before a second exposure to 3 hours of OGD. Khaspekov et al. [40] used mixed neuroglial hippocampal cell cultures in their study and found that a 60 min of OGD preconditioning could protect against 90 min of OGD performed 1 and 2 days later. Similarly, Grabb and Choi [41] used cells from cortices of fetal mice to test if exposure to periods of OGD (5–30 min) that were too brief to cause cell death could protect a subsequent exposure to lethal ODG (45–55 min) performed 24 hours later. They also found that the pre-exposure did provide significant protection against the lethal exposure [41]. Neuroprotection was lost if the interval between the preconditioning and the severe insult was shortened to 7 hours or lengthened to 72 hours [41]. Interestingly, they also reported that the preconditioned cultures were not protected against NMDA, kainate-, or glutamate-induced neuronal death [41]. This is contrast with the study by Tauskela et al. [42] who reported that subjecting rat cortical cultures to a preconditioning OGD paradigm provided cross-tolerance to NMDA-induced cell death. They also found that NMDA receptor blockade during preconditioning by OGD eliminated tolerance [42]. Another study comparing various preconditioning manipulations to OGD found that cycloheximide, heat stress, MK801 were as protective as OGD preconditioning in both acute and delayed models of ischemia-induced neuronal death [43]. Similar results have been reported using hippocampal slice cultures [44], after combined deprivation of glucose and amino acids [45], and after exposure to neuronal cultures to various agents including anesthetic agents and diazoxide [46,47], mild hypoxic insults [40], as well as stimulation of adenosine receptors [48]. Interestingly, Badaut et al. [49] used the OGD model in organotypic cultures of the hippocampus and demonstrated that preconditioning provided protection against cell death and the transient loss of evoked potential responses.

## Other models of brain tolerance

In addition to ischemia preconditioning, there are other pretreatment paradigms that have been shown to protect against ischemic injuries. These include hyperthermia [50], lipopolysaccharide (LPS) pretreatment [51,52] and treatment with anesthetic agents [53,54] among others. A small dose of LPS given systemically confers ischemic protection in the brain, a process that appears to involve activation of an inflammatory response before ischemia [51]. LPS preconditioning in the brain shares some hallmarks that are characteristic of ischemic preconditioning in the brain. These include delayed induction of tolerance after preconditioning and dependence on de novo protein synthesis [55]. The systemic route of LPS administration and the induction of some systemic changes are unique aspects of LPS preconditioning that might offer some clinical advantages. Other models of preconditioning that remain to be thoroughly investigated include hypoxic insults in a neonatal rat model [56,57], spreading depression [58,59], and the induction of seizures [60]. Of significant interest are recent studies that have demonstrated that exercise preconditioning might provide substantial benefit against ischemic damage [61–63] and heat strokes [64] in rodents.

## Mechanisms of brain tolerance

Mechanistic studies of ischemic tolerance are very important to the development of strategies to treat ischemic strokes. These studies have focused on types of ischemic tolerance. The original or classic type of ischemic tolerance is a delayed type of tolerance that requires new protein synthesis and engenders neuronal protection 24–72 hours after the preconditioning stimulus [65]. In contrast, rapid ischemic tolerance does not require new protein synthesis and produces neuroprotection within 1 hour of the preconditioning event [36,66]. Delayed tolerance develops over time, with protection against subsequent injury being present at 24 to 48 hours after the preconditioning event, peaking at around 3 days and slowly disappearing over a week period. Rapid tolerance develops within a few minutes and lasts less than 3 days [36]. Understanding the cellular and molecular mechanisms that underlie the protective effects of preconditioning has significant clinical implications. These mechanisms appear to involve counteracting the pathways that cause ischemia-induced neuronal death. The fact that many strokes are preceded by transient ischemic attacks [12] suggests that it might be possible to develop approaches that are akin to preconditioning-induced protection in humans.

### Glutamate receptors and excitotoxicity

Cerebral ischemia results in a rapid depletion of energy stores that triggers a complex cascade of cellular events such as cellular depolarization and  $\text{Ca}^{2+}$  influx, resulting in excitotoxic cell death [14,15]. A role for NMDA receptor signaling in ischemic preconditioning in the CNS is supported by reports that NMDA receptor antagonists can alter the development of ischemic tolerance induced by brief repeated ischemic insults in gerbil brains [26], by OGD in mouse cortical cultures [41], and hypoxia-induced damage in hippocampal slices [67]. Moreover, exposure to sublethal NMDA concentrations provided protection to neurons against lethal death stimuli applied at later time points [68]. Using the gerbil model, it has been shown that binding of [ $^3\text{H}$ ]MK-801 and [ $^3\text{H}$ ] $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) to excitatory NMDA and AMPA receptors were significantly decreased in the hippocampus of animals rendered tolerant to the degenerative effects of ischemic insults [69]. The expression of GluR2 protein is also significantly decreased in neuronal populations that survived in the tolerant gerbil brain [70]. The mRNA for glutamate receptor, ionotropic delta 2, was reported to be down-regulated in the mouse brain after preconditioning [71]. In contrast, [ $^3\text{H}$ ]muscimol binding to GABA(A) receptors in CA1 neurons was transiently but significantly increased after preconditioning but not after ischemic injuries [69]. These results suggest that preconditioning might cause a change in the balance between excitotoxic and inhibitory mechanisms in the brain in such a way that pro-inhibitory forces might be more prominent in the tolerant brain.

Lin et al. [72] used OGD model in cultured cortical neurons to investigate the mechanisms of protection conferred by glutamate preconditioning. Pretreatment of neurons with NMDA receptor antagonists prevented OGD-induced cell death whereas AMPA receptor and voltage-dependent  $\text{Ca}^{2+}$  channel blockers did not. Neurons preconditioned with glutamate exhibited resistance to damage induced by OGD, with the observed protection depending on the duration of preconditioning exposure and the interval between preconditioning exposure and test challenge. Protective efficacy was blocked by the NMDA or AMPA receptor antagonists.

### Free radical mechanisms

Brain ischemia is known to induce the generation of oxygen- and nitrogen-based free radicals which are involved in causing much of the damage observed in the ischemic brain [73]. Superoxide can be generated through the actions of xanthine oxidase, leakage from the mitochondrial electron transport chain, and via the actions of other oxidases [74]. Nitric oxide can be generated by the action of nitric oxide synthases [75], whose activation during ischemic



injuries is dependent on activation of glutamate receptors (see above). Nitric oxide and superoxide can interact to form the toxic peroxynitrite [75]. Some studies have suggested that preconditioning might exert its protective effects by preventing the production of free radicals or by inhibiting their toxic effects on the brain [76]. For example, Toyoda et al. [77] have reported that ischemic preconditioning which reduced the volume of cerebral infarction also caused significant increases in the activity of the antioxidant enzyme superoxide dismutase. Volatile anesthetics were also reported to exert their protective effects via inducible nitric oxide synthase-dependent mechanisms [78]. Heme oxygenase-1 (HO-1), the rate-limiting enzyme in the degradation of heme to produce bile pigments and carbon monoxide, is induced by a variety of factors such as heat, ischemia, and hydrogen peroxide [79]. Induction of HO-1 has been shown to exert protective activity against ischemic damage [80] and the protective effects of the anesthetic agent, isoflurane, have been reported to depend on increased HO-1 expression in OGD-induced neuronal injury [81].

### Transduction signaling pathways

Activation of kinase pathways is thought to play integral role in the development of the tolerant heart [82]. Similarly, a few reports have suggested a role for the mitogen-activated protein kinase pathway in preconditioning-induced neuroprotection. For example, Shamloo et al. [83] had investigated the role of MEK1/2 and ERK1/2 in ischemic preconditioning. They found that 3 min of ischemic preconditioning caused increased expression of phosphorylated MEK and of phosphorylated ERK in the rat hippocampus. In addition, 9 min of lethal ischemia caused increases in phosphorylated ERK in both sham and preconditioned animals. However, the levels of phosphorylated ERK had returned to normal in the tolerant hippocampi whereas it stayed elevated in the damaged hippocampi 24 hours after ischemic damage [83]. In vivo studies have also suggested that nitric oxide-dependent activation of the Ras-extracellular regulated kinase cascade participates in the development of OGD tolerance in cortical neurons [84]. These findings have been replicated in the rat hippocampus where sustained increases in ERK phosphorylation have been found [85]. In the heart, ERK1/2 activation has been shown to participate in isoflurane preconditioning through the upregulation of hypoxia-inducible factor-1  $\alpha$  (HIF-1 $\alpha$ ) and vascular endothelial growth factor [86]. ERK5 activation also participates in the protective effects of ischemic preconditioning [87,88]. Jia et al. [89] have also reported that ERK and novel PKC epsilon are involved in OGD-induced neuroprotection in hippocampal slices from mice. These results are consistent, in part, with previous reports that ischemia- and NMDA-induced tolerance involved activation of PKC epsilon in organotypic hippocampal slice cultures [90,91]. The neuroprotective effects of PKC epsilon appear to involve phosphorylation of the mitochondrial K(+) ATP channel [92]. Other isoforms of PKC such as PKC alpha and delta have also been implicated in the mechanisms of ischemic preconditioning [93,94].

Nishimura et al. [95] used the gerbil model and showed that, after 2-minute preconditioning, there was enhanced p38 immunoreactivity in CA1 and CA3 neurons after 6 hours of reperfusion. SB203580-induced inhibition of active p38 30 minutes before the 2-minute ischemia reduced the ischemic tolerance effect. In the hippocampal CA1 region, preconditioning has also been reported to block MLK3 activation after lethal ischemia, an effect that is mediated by Akt1 activation through NMDA receptor stimulation [96]. Miao et al. [97] also reported that ischemic preconditioning caused down-regulation of MLK3 and JNK1/2 in the rat brain in an Akt1-dependent fashion.

### Transcription factors

Ischemic injuries are associated with the activation of a number of transcription factors [98]. For example, adaptive responses to ischemic injuries in the brain have been shown to involve families of transcription factors including members of the activator protein 1 (AP-1) [97],

cAMP response element-binding protein (CREB) [99], and HIFs [100] among others. These are discussed below.

Dimeric AP-1 complexes are involved in the control of cell proliferation, differentiation, and death via the regulation of multiple gene families [101,102]. Members of the AP-1 transcription factors include c-fos, fra-1, fra-2, fosB, c-jun, junB, and junD [103]. A number of studies have suggested that ischemic injuries are associated with significant changes in their expression. For example, Kiessling et al. [104] have reported that, after 5 min of ischemia, c-fos and Krox-24 mRNAs were increased in all hippocampal subpopulations peaking at 1 h after recirculation. Increased immediate-early gene (IEG) proteins occurred in neuronal populations that were resistant to ischemia. An et al. [105] also reported on the expression of c-fos, c-jun, junB and jun D in a rat model of ischemia for 90 minutes, which led to large cortical infarction, caused substantial increases in c-fos and junB expression in the brain, with c-jun showing less of an increase. Delayed expression of JunB was also reported to precede neuronal death after global ischemia in the gerbil brain [106]. Yoneda et al. [107] used gel retardation electrophoresis and found that transient forebrain ischemia for 5 min caused potentiation of AP-1 binding in the hippocampal CA1 and CA3 regions of gerbils that had experienced ischemia for 2 min two days before, a process known to lead to the development of tolerance to subsequent severe ischemia. In contrast, ischemia for 5 min caused prolonged potentiation of AP-1 binding in the vulnerable CA1 subfield of the gerbils with prior ischemia for 5 min 14 days before, a process known to cause delayed death of pyramidal neurons in the CA1 area. These increases were not observed in the resistant CA3 subfield of the hippocampus [107]. Using a model of preconditioning which uses a sublethal ischemic stimulus (2.5 min), Kapinya et al. [108] measured DNA binding activity of the AP-1 transcription factor complex in the brain after severe ischemic injuries and in preconditioned gerbil brains. Ischemic tolerance was associated with short increases in AP-1 binding activity which peaked at 3 hours. Similar changes occurred in cells that are destined to survive in the hippocampal CA1 areas. Dhodda et al. [109] found increases in c-jun during ischemic preconditioning. These authors also reported that preconditioning blocked ischemia-induced increases in c-fos, c-jun and junB. In contrast, Sommer et al. [110] reported that there were selective increases in c-JUN expression in the gerbil hippocampus during and after the acquisition of the tolerant state. These discrepancies suggest that the role of AP-1 transcription factors in the development of ischemic tolerance is a complex issue that needs to be dissected further.

Ischemic injury is also associated with phosphorylation of CREB and increases in the expression of CREB-dependent genes in the brain [99,111]. CREB is necessary for cellular proliferation, survival and differentiation [112]. In the brain, CREB-induced gene expression participates in learning and memory, as well as in neuron survival and differentiation [113]. CREB is very important in stimulus-transcription coupling and in receptor-mediated changes in gene expression [112]. These changes are probably mediated via stimulation of glutamate receptors and subsequent increases in cytosolic calcium. This pathway is thought to also be involved in the manifestation of ischemic preconditioning because Mabuchi et al. [114] have reported that increased CREB phosphorylation might occur as a protective adaptation to ischemic injury. Of more direct relevance, Lee et al. [115] have reported that preconditioning is associated with CREB activation. Furthermore, inhibition of CREB-mediated gene transcription with either CRE-decoy oligonucleotide or protein kinase inhibitors interfered with the development of ischemic tolerance [116]. Rybnikova et al. [117] also recently reported prolonged expression of phosphorylated CREB after preconditioning. Because CREB is involved in the regulation of many genes, it will be important to identify which specific genes are involved in the actions of this transcription factor.

HIF-1 was cloned during a search for proteins that participate in the regulation of genes that are involved in adaptation to ischemic injuries [118]. HIF-1 $\alpha$  can partner with HIF-1 $\beta$  and

translocate to the nucleus to regulate the expression of genes involved in hypoxic adaptation [119]. This idea is supported by increases in HIF-1 $\alpha$  immunoreactivity in hypoxic brains [120]. Treatment with desferrioxamine which protects against cell death in models of ischemia causes stabilization of HIF-1 $\alpha$  in vitro and in vivo [119,121].

### Chaperones

Chaperones are known to be involved in protecting various systems against an array of insults including cerebral ischemia [122]. Several laboratories have studied the potential role of chaperones in both in vitro and in vivo models of the preconditioned response. Liu et al. [123] found that induction of heat shock protein 70 (HSP70) correlated with preconditioning-induced protection in the rat hippocampus. Similarly, Kato et al. [8] investigated the potential role of the low-molecular weight stress proteins, 27-kDa heat shock protein (HSP27) and  $\alpha$ B crystallin, and of HSP70 in ischemic tolerance in the rat brain. They found that the induction of both HSP27 and HSP70, but not of  $\alpha$ B crystallin, had a good temporal correlation with the induction of ischemic tolerance [8]. Chen et al. [124] have conducted experiments to test the involvement of the inducible HSP70, glucose-regulated protein-75 (GRP75) and GRP78 in ischemic tolerance. They found that the expression of HSP70, but not that of GRP75 or GRP78, increased during times when ischemic tolerance was present but not after [124]. Tanaka et al. [125] also found increases in HSP40 in the hippocampus of tolerant mice. In addition, they observed parallel increases in HSP70 in these mice [125]. Microarray analyses have also found HSP70 and small heat shock protein HSPB2 to be upregulated in the mouse brain after preconditioning [71]. Dhodda et al. [109] have documented increases in the expression of HSP27, HSP70, and HSP90 using microarray and proteomic analyses. A study by Hayashi et al. [126] also reported significant increases in GRP78 at 2 days, a time which coincided with the time of tolerance in the rat hippocampus.

In addition to HSP40 and HSP70, Yagita et al. [127] assessed the expression profiles of all members of the HSP110 family including ischemia responsive protein 94, HSP110/105, and osp94/apg-1. They reported that the expression of HSP110/105 mRNA was increased from 4 to 24 hours after a 6-minute or longer ischemic period, with increased expression occurring first in the dentate gyrus and, later, in the pyramidal layer. They also found that the changes in HSP110/105 expression after ischemia were similar to those of inducible HSP70, which was previously reported to be involved in preconditioning-related protection [8,124]. Tolerant CA1 pyramidal neurons expressed both HSP70 and HSP110/105, thus suggesting that these two chaperones might work in concert to protect neurons against subsequent lethal damage [127]. When taken together, these studies indicate that HSPs might play an integral role in the protective effects observed after preconditioning. Some of these changes might occur in astrocytes that might be induced to release several factors to protect neurons against ischemic injuries (see Brown [122] for further discussion of the interactions of chaperones in the brain).

### Neuroinflammatory responses

Strokes are thought to be accompanied by inflammatory responses that might participate, in part, in the delayed effects of neuronal survival [128]. LPS preconditioning suppresses the cellular inflammatory response to ischemia in the brain and circulation. Diminished activation of cellular inflammatory responses that ordinarily exacerbate ischemic injury may contribute to neuroprotection induced by LPS preconditioning [51]. Glial cells, in particular astrocytes, have always been viewed as supporters of neuronal function. Only recently a very active role for glial cells has been emerging in physiology and pathophysiology. Specific pathways have been identified by which these cells can protect or even help to regenerate brain tissue after acute insults [129]. Ischemic damage is associated with reactive astrocytosis which is characterized by very obvious structural changes [130]. Astrocytes secrete cytokines and chemokines [131].



Microglia are resident macrophages that play immunocompetent and phagocytic functions in the brain [132]. In the case of ischemia, microglial cells undergo morphologic transformation and secrete a number of substances that participate in either protoxic or protective mechanisms [132,133]. Minocycline, a tetracycline family antibiotic, has been reported to protect against ischemic damage by blocking microglial activation [134,135]. It also should be noted that microglia/macrophages or their secreted factors may actually protect cells against damage caused by glutamate [136]. Thus, the role of microglia cells in the preconditioned brain needs to be further investigated.

### Trophic factors

Trophic factors are involved in the process of neurite outgrowth and in cell survival in the brain [137]. These neurotrophic factors which include brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) are present in high concentrations in the hippocampal formation and cerebral cortex [138]. The intracellular pathways used by the neurotrophic factors are dependent on their interactions with high-affinity receptors (TrkA for nerve growth factor (NGF), TrkB for BDNF and TrkC for NT-3) [138,139]. Following cerebral ischemia or hypoglycemic coma, the levels of NGF and BDNF but not of NT-3 are decreased in hippocampal neurons [140–142]. However, the situation is different for the receptors, in that only the expression of TrkB is increased in the hippocampal formation [141]. These observations are consistent, in part, with the reports that NGF and BDNF can protect hippocampal CA1 neurons against ischemic cell damage [143–145]. Given these results, the potential role of trophic factors in ischemic preconditioning has been investigated [146]. It was found that increases in the levels of NGF and BDNF occurred within the first 6 hours after ischemic preconditioning manipulations such as short-term global cerebral ischemia [147]. Preconditioning applied 3 days earlier was able to attenuate increases in the levels of BDNF mRNA observed at 12 h after reperfusion using a rat model [148]. More recently, Lee et al. [149] showed that NGF, BDNF, and their receptors recover better in tolerant hippocampal neurons. Because trophic factors are so important during development and participate so actively in neuroplastic and neuroprotective mechanisms in the brain, more investigations on their roles in the tolerant brain are warranted.

### Other mechanisms

Attempts have been made, using unbiased approaches, to identify genes that might be involved in the development of the tolerant brain [71,150]. The facts that it takes several hours to induce delayed ischemic brain tolerance [25] and that protein synthesis is also necessary for its manifestation [65] have led to the suggestion that changes in the transcriptome might play a role in its appearance. On the other hand, short-term tolerance might be dependent on activation of the ubiquitin-proteasome pathway [151]. In order to test the role of gene expression in delayed ischemic preconditioning, Stenzel-Poore et al. [71] used unbiased microarray analyses and found that genes involved in responses to stress, metabolism, regulation of apoptosis, and signal transduction were upregulated by ischemia. In contrast, preconditioning of the brain causes downregulation of many genes involved in these pathways. Moreover, preconditioning prevented the upregulation of the genes that were induced by the lethal ischemic stimulus. Dhodda et al. [109] also used microarray analyses and reported that ischemic preconditioning was associated with increases in Bcl-2, Bid, caspase-2 and LICE. The increases in Bcl-2 expression are probably mediated by CREB activation [152]. Glutamate preconditioning, using the OGD model, is also associated with increased Bcl-2 expression that was blocked by the calmodulin kinase inhibitor, KN93, by the protein kinase inhibitor, staurosporine, and by a CRE-decoy oligonucleotide [72]. Dhodda et al. [109] have also reported increases in SMAD1, SMAD7, TGF- $\alpha$ , TGF- $\beta$  after ischemic preconditioning. It is important to note that recent studies have suggested that Toll-like receptors (TLR), well known

components of the innate immune system [153], might play a role in preconditioning [154]. Indeed, systemic administration of TLR ligands cause tolerance to ischemic injuries, a process that might involve increased expression of neuroprotective anti-inflammatory substances [155].

## Concluding Remarks

The development of the preconditioning brain is dependent on the activation of several neuroprotective pathways. These changes are associated with both transcriptional and translational changes that bring the brain to another homeostatic state that allows it to be refractory to some lethal insults. In the case of ischemic strokes, there appear to be several triggers of the preconditioned states and these include heat, anesthetic agents, and seizures. Because there are substantial degrees of cross-tolerance between the various triggers of preconditioning, it is possible to suggest that elucidation of the mechanisms involved in anesthetic-induced preconditioning might impact significantly on the treatment of the delayed neurodegenerative changes that accompany ischemic strokes. The elucidation of these pathways might also impact on the treatment of older individuals who suffer from mild cognitive deficits. Although this review has focused mostly on the use of subtoxic insults to generate a tolerant state, these approaches might be fraught with ethical dilemma that might not be easily overcome. Approaches such as exercise preconditioning which has recently been shown to reduce brain damage might be less controversial and will need to be further investigated.

## Acknowledgements

This paper is supported by the Intramural Research Program of the National Institute on Drug Abuse, NIH, DHHS. The authors also thank the reviewers whose suggestions helped to improve the paper.

## REFERENCES

1. Voss T, Ravina B. Neuroprotection in Parkinson's disease: myth or reality? *Curr Neurol Neurosci Rep* 2008;8:304–309. [PubMed: 18590614]
2. Geft IL, Fishbein MC, Ninomiya K, Hashida J, Chaux E, Yano J, J YR, Genov T, Shell W, Ganz W. Intermittent brief periods of ischemia have a cumulative effect and may cause myocardial necrosis. *Circulation* 1982;66:1150–1153. [PubMed: 7139894]
3. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986;74:1124–1136. [PubMed: 3769170]
4. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. *Am J Physiol* 1986;251:H1306–H1315. [PubMed: 3789183]
5. Carroll CM, Carroll SM, Overgoor ML, Tobin G, Barker JH. Acute ischemic preconditioning of skeletal muscle prior to flap elevation augments muscle-flap survival. *Plast Reconstr Surg* 1997;100:58–65. [PubMed: 9207659]
6. Clavien PA, Selzner M, Rudiger HA, Graf R, Kadry Z, Rousson V, Jochum W. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. *Ann Surg* 2003;238:843–852. [PubMed: 14631221]
7. Koti RS, Seifalian AM, Davidson BR. Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications. *Dig Surg* 2003;20:383–396. [PubMed: 12840597]
8. Kato H, Liu Y, Kogure K, Kato K. Induction of 27-kDa heat shock protein following cerebral ischemia in a rat model of ischemic tolerance. *Brain Res* 1994;634:235–244. [PubMed: 8131073]
9. Calabrese EJ. Converging concepts: adaptive response, preconditioning, and the Yerkes-Dodson Law are manifestations of hormesis. *Ageing Res Rev* 2008;7:8–20. [PubMed: 17768095]
10. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. *Trends Neurosci* 2003;26:248–254. [PubMed: 12744841]

11. Zhao H. The protective effect of ischemic postconditioning against ischemic injury: from the heart to the brain. *J Neuroimmune Pharmacol* 2007;2:313–318. [PubMed: 18040849]
12. Fisher M. Stroke and TIA: epidemiology, risk factors, and the need for early intervention. *Am J Manag Care* 2008;14:S204–S211. [PubMed: 18611102]
13. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2008;117:e25–e146. [PubMed: 18086926]
14. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. *Stroke* 2003;34:214–223. [PubMed: 12511777]
15. Hossmann KA. Pathophysiology and therapy of experimental stroke. *Cell Mol Neurobiol* 2006;26:1057–1083. [PubMed: 16710759]
16. Turner R, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. *Drug News Perspect* 2007;20:221–226. [PubMed: 17637934]
17. Love S. Oxidative stress in brain ischemia. *Brain Pathol* 1999;9:119–131. [PubMed: 9989455]
18. Pulsinelli WA, Jacewicz M, Levy DE, Petito CK, Plum F. Ischemic brain injury and the therapeutic window. *Ann N Y Acad Sci* 1997;835:187–193. [PubMed: 9616773]
19. Nighoghossian N, Wiart M, Cakmak S, Berthezene Y, Derex L, Cho TH, Nemoz C, Chapuis F, Tisserand GL, Pialat JB, Trouillas P, Froment JC, Hermier M. Inflammatory response after ischemic stroke: a USPIO-enhanced MRI study in patients. *Stroke* 2007;38:303–307. [PubMed: 17170357]
20. Arboix A, Cabeza N, Garcia-Eroles L, Massons J, Oliveres M, Targa C, Balcells M. Relevance of transient ischemic attack to early neurological recovery after nonlacunar ischemic stroke. *Cerebrovasc Dis* 2004;18:304–311. [PubMed: 15331877]
21. Moncayo J, de Freitas GR, Bogousslavsky J, Altieri M, van Melle G. Do transient ischemic attacks have a neuroprotective effect? *Neurology* 2000;54:2089–2094. [PubMed: 10851368]
22. Zsuga J, Gesztelyi R, Juhasz B, Kemeny-Beke A, Fekete I, Csiba L, Bereczki D. Prior transient ischemic attack is independently associated with lesser in-hospital case fatality in acute stroke. *Psychiatry Clin Neurosci* 2008;62:705–712. [PubMed: 19068008]
23. Gross ER, Gross GJ. Ischemic Preconditioning And Myocardial Infarction: An Update and Perspective. *Drug Discov Today Dis Mech* 2007;4:165–174. [PubMed: 18701939]
24. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. *Brain Res* 1982;239:57–69. [PubMed: 7093691]
25. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N, Fukunaga R, Kimura K, Mikoshiba K. 'Ischemic tolerance' phenomenon found in the brain. *Brain Res* 1990;528:21–24. [PubMed: 2245337]
26. Kato H, Liu Y, Araki T, Kogure K. MK-801, but not anisomycin, inhibits the induction of tolerance to ischemia in the gerbil hippocampus. *Neurosci Lett* 1992;139:118–121. [PubMed: 1407677]
27. Miyashita K, Abe H, Nakajima T, Ishikawa A, Nishiura M, Sawada T, Naritomi H. Induction of ischaemic tolerance in gerbil hippocampus by pretreatment with focal ischaemia. *Neuroreport* 1994;6:46–48. [PubMed: 7703426]
28. Ohtsuki T, Ruetzler CA, Tasaki K, Hallenbeck JM. Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons. *J Cereb Blood Flow Metab* 1996;16:1137–1142. [PubMed: 8898685]
29. Dowden J, Corbett D. Ischemic preconditioning in 18- to 20-month-old gerbils: long-term survival with functional outcome measures. *Stroke* 1999;30:1240–1246. [PubMed: 10356107]
30. Kitagawa K, Matsumoto M, Ohtsuki T, Kuwabara K, Mabuchi T, Yagita Y, Hori M, Yanagihara T. Extended neuronal protection induced after sublethal ischemia adjacent to the area with delayed neuronal death. *Neuroscience* 2000;96:141–146. [PubMed: 10683419]
31. Liu Y, Kato H, Nakata N, Kogure K. Protection of rat hippocampus against ischemic neuronal damage by pretreatment with sublethal ischemia. *Brain Res* 1992;586:121–124. [PubMed: 1380876]
32. Simon RP, Niuro M, Gwinn R. Prior ischemic stress protects against experimental stroke. *Neurosci Lett* 1993;163:135–137. [PubMed: 8309618]

33. Glazier SS, O'Rourke DM, Graham DI, Welsh FA. Induction of ischemic tolerance following brief focal ischemia in rat brain. *J Cereb Blood Flow Metab* 1994;14:545–553. [PubMed: 8014201]
34. Matsushima K, Hakim AM. Transient forebrain ischemia protects against subsequent focal cerebral ischemia without changing cerebral perfusion. *Stroke* 1995;26:1047–1052. [PubMed: 7762022]
35. Belayev L, Ginsberg MD, Alonso OF, Singer JT, Zhao W, Busto R. Bilateral ischemic tolerance of rat hippocampus induced by prior unilateral transient focal ischemia: relationship to c-fos mRNA expression. *Neuroreport* 1996;8:55–59. [PubMed: 9051752]
36. Perez-Pinzon MA, Xu GP, Dietrich WD, Rosenthal M, Sick TJ. Rapid preconditioning protects rats against ischemic neuronal damage after 3 but not 7 days of reperfusion following global cerebral ischemia. *J Cereb Blood Flow Metab* 1997;17:175–182. [PubMed: 9040497]
37. Goldberg MP, Choi DW. Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. *J Neurosci* 1993;13:3510–3524. [PubMed: 8101871]
38. Martin RL, Lloyd HG, Cowan AI. The early events of oxygen and glucose deprivation: setting the scene for neuronal death? *Trends Neurosci* 1994;17:251–257. [PubMed: 7521086]
39. Bruer U, Weih MK, Isaev NK, Meisel A, Ruscher K, Bergk A, Trendelenburg G, Wiegand F, Victorov IV, Dirnagl U. Induction of tolerance in rat cortical neurons: hypoxic preconditioning. *FEBS Lett* 1997;414:117–121. [PubMed: 9305743]
40. Khaspekov L, Shamloo M, Victorov I, Wieloch T. Sublethal in vitro glucose-oxygen deprivation protects cultured hippocampal neurons against a subsequent severe insult. *Neuroreport* 1998;9:1273–1276. [PubMed: 9631411]
41. Grabb MC, Choi DW. Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors. *J Neurosci* 1999;19:1657–1662. [PubMed: 10024352]
42. Tauskela JS, Comas T, Hewitt K, Monette R, Paris J, Hogan M, Morley P. Cross-tolerance to otherwise lethal N-methyl-D-aspartate and oxygen-glucose deprivation in preconditioned cortical cultures. *Neuroscience* 2001;107:571–584. [PubMed: 11720781]
43. Meloni BP, Majda BT, Knuckey NW. Evaluation of preconditioning treatments to protect near-pure cortical neuronal cultures from in vitro ischemia induced acute and delayed neuronal death. *Brain Res* 2002;928:69–75. [PubMed: 11844473]
44. Hassen GW, Tian D, Ding D, Bergold PJ. A new model of ischemic preconditioning using young adult hippocampal slice cultures. *Brain Res Brain Res Protoc* 2004;13:135–143. [PubMed: 15296850]
45. Gaspar T, Kis B, Snipes JA, Lenzser G, Mayanagi K, Bari F, Busija DW. Transient glucose and amino acid deprivation induces delayed preconditioning in cultured rat cortical neurons. *J Neurochem* 2006;98:555–565. [PubMed: 16805846]
46. Bickler PE, Zhan X, Fahlman CS. Isoflurane preconditions hippocampal neurons against oxygen-glucose deprivation: role of intracellular Ca<sup>2+</sup> and mitogen-activated protein kinase signaling. *Anesthesiology* 2005;103:532–539. [PubMed: 16129978]
47. Kis B, Rajapakse NC, Snipes JA, Nagy K, Horiguchi T, Busija DW. Diazoxide induces delayed preconditioning in cultured rat cortical neurons. *J Neurochem* 2003;87:969–980. [PubMed: 14622127]
48. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K<sup>+</sup> channels in cerebral ischemic preconditioning. *Proc Natl Acad Sci U S A* 1995;92:4666–4670. [PubMed: 7753861]
49. Badaut J, Hirt L, Price M, de Castro Ribeiro M, Magistretti PJ, Regli L. Hypoxia/hypoglycemia preconditioning prevents the loss of functional electrical activity in organotypic slice cultures. *Brain Res* 2005;1051:117–122. [PubMed: 16005858]
50. Arieli Y, Eynan M, Gancz H, Arieli R, Kashi Y. Heat acclimation prolongs the time to central nervous system oxygen toxicity in the rat. Possible involvement of HSP72. *Brain Res* 2003;962:15–20. [PubMed: 12543451]
51. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. *Stroke* 2004;35:2576–2581. [PubMed: 15375302]
52. Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning protects against the cytotoxic effects of TNF $\alpha$

- after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. *J Cereb Blood Flow Metab* 2007;27:1663–1674. [PubMed: 17327883]
53. Clarkson AN. Anesthetic-mediated protection/preconditioning during cerebral ischemia. *Life Sci* 2007;80:1157–1175. [PubMed: 17258776]
54. Kitano H, Kirsch JR, Hurn PD, Murphy SJ. Inhalational anesthetics as neuroprotectants or chemical preconditioning agents in ischemic brain. *J Cereb Blood Flow Metab* 2007;27:1108–1128. [PubMed: 17047683]
55. Bordet R, Deplanque D, Maboudou P, Puisieux F, Pu Q, Robin E, Martin A, Bastide M, Leys D, Lhermitte M, Dupuis B. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. *J Cereb Blood Flow Metab* 2000;20:1190–1196. [PubMed: 10950379]
56. Gidday JM, Fitzgibbons JC, Shah AR, Park TS. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. *Neurosci Lett* 1994;168:221–224. [PubMed: 8028780]
57. Gidday JM, Shah AR, Maceren RG, Wang Q, Pelligrino DA, Holtzman DM, Park TS. Nitric oxide mediates cerebral ischemic tolerance in a neonatal rat model of hypoxic preconditioning. *J Cereb Blood Flow Metab* 1999;19:331–340. [PubMed: 10078885]
58. Kobayashi S, Harris VA, Welsh FA. Spreading depression induces tolerance of cortical neurons to ischemia in rat brain. *J Cereb Blood Flow Metab* 1995;15:721–727. [PubMed: 7673367]
59. Matsushima K, Hogan MJ, Hakim AM. Cortical spreading depression protects against subsequent focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 1996;16:221–226. [PubMed: 8594053]
60. Plamondon H, Blondeau N, Heurteaux C, Lazdunski M. Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels. *J Cereb Blood Flow Metab* 1999;19:1296–1308. [PubMed: 10598933]
61. Ding YH, Mrizek M, Lai Q, Wu Y, Reyes R Jr, Li J, Davis WW, Ding Y. Exercise preconditioning reduces brain damage and inhibits TNF-alpha receptor expression after hypoxia/reoxygenation: an in vivo and in vitro study. *Curr Neurovasc Res* 2006;3:263–271. [PubMed: 17109621]
62. Ding YH, Young CN, Luan X, Li J, Rafols JA, Clark JC, McAllister JP 2nd, Ding Y. Exercise preconditioning ameliorates inflammatory injury in ischemic rats during reperfusion. *Acta Neuropathol* 2005;109:237–246. [PubMed: 15616790]
63. Guo M, Cox B, Mahale S, Davis W, Carranza A, Hayes K, Sprague S, Jimenez D, Ding Y. Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates blood-brain barrier dysfunction in stroke. *Neuroscience* 2008;151:340–351. [PubMed: 18160227]
64. Chen YW, Chen SH, Chou W, Lo YM, Hung CH, Lin MT. Exercise pretraining protects against cerebral ischaemia induced by heat stroke in rats. *Br J Sports Med* 2007;41:597–602. [PubMed: 17496074]
65. Barone FC, White RF, Spera PA, Ellison J, Currie RW, Wang X, Feuerstein GZ. Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. *Stroke* 1998;29:1937–1951. [PubMed: 9731622]
66. Perez-Pinzon MA, Born JG. Rapid preconditioning neuroprotection following anoxia in hippocampal slices: role of the K+ ATP channel and protein kinase C. *Neuroscience* 1999;89:453–459. [PubMed: 10077327]
67. Kasischke K, Ludolph AC, Riepe MW. NMDA-antagonists reverse increased hypoxic tolerance by preceding chemical hypoxia. *Neurosci Lett* 1996;214:175–178. [PubMed: 8878112]
68. Bhawe SV, Ghoda L, Hoffman PL. Brain-derived neurotrophic factor mediates the anti-apoptotic effect of NMDA in cerebellar granule neurons: signal transduction cascades and site of ethanol action. *J Neurosci* 1999;19:3277–3286. [PubMed: 10212287]
69. Sommer C, Fahrner A, Kiessling M. [3H]muscimol binding to gamma-aminobutyric acid(A) receptors is upregulated in CA1 neurons of the gerbil hippocampus in the ischemia-tolerant state. *Stroke* 2002;33:1698–1705. [PubMed: 12053014]
70. Sommer C, Kiessling M. Ischemia and ischemic tolerance induction differentially regulate protein expression of GluR1, GluR2, and AMPA receptor binding protein in the gerbil hippocampus: GluR2



(GluR-B) reduction does not predict neuronal death. *Stroke* 2002;33:1093–1100. [PubMed: 11935066]

71. Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, Mori M, Meller R, Rosenzweig HL, Tobar E, Shaw TE, Chu X, Simon RP. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. *Lancet* 2003;362:1028–1037. [PubMed: 14522533]
72. Lin CH, Chen PS, Gean PW. Glutamate preconditioning prevents neuronal death induced by combined oxygen-glucose deprivation in cultured cortical neurons. *Eur J Pharmacol* 2008;589:85–93. [PubMed: 18589412]
73. Carbonell T, Rama R. Iron, oxidative stress and early neurological deterioration in ischemic stroke. *Curr Med Chem* 2007;14:857–874. [PubMed: 17430141]
74. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. *Neurochem Int* 1998;32:117–131. [PubMed: 9542724]
75. Guix FX, Uribealago I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. *Prog Neurobiol* 2005;76:126–152. [PubMed: 16115721]
76. Busija DW, Gaspar T, Domoki F, Katakam PV, Bari F. Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning. *Adv Drug Deliv Rev* 2008;60:1471–1477. [PubMed: 18652858]
77. Toyoda T, Kassell NF, Lee KS. Induction of ischemic tolerance and antioxidant activity by brief focal ischemia. *Neuroreport* 1997;8:847–851. [PubMed: 9141050]
78. Kapinya KJ, Lowl D, Futterer C, Maurer M, Waschke KF, Isaev NK, Dirnagl U. Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent. *Stroke* 2002;33:1889–1898. [PubMed: 12105371]
79. Schipper HM. Heme oxygenase-1: transducer of pathological brain iron sequestration under oxidative stress. *Ann N Y Acad Sci* 2004;1012:84–93. [PubMed: 15105257]
80. Panahian N, Yoshiura M, Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. *J Neurochem* 1999;72:1187–1203. [PubMed: 10037492]
81. Li Q, Zhu Y, Jiang H, Xu H, Liu H. Up-regulation of heme oxygenase-1 by isoflurane preconditioning during tolerance against neuronal injury induced by oxygen glucose deprivation. *Acta Biochim Biophys Sin (Shanghai)* 2008;40:803–810. [PubMed: 18776993]
82. Costa AD, Garlid KD. Intramitochondrial signaling: interactions among mitoKATP, PKCepsilon, ROS, and MPT. *Am J Physiol Heart Circ Physiol* 2008;295:H874–H882. [PubMed: 18586884]
83. Shamloo M, Rytter A, Wieloch T. Activation of the extracellular signal-regulated protein kinase cascade in the hippocampal CA1 region in a rat model of global cerebral ischemic preconditioning. *Neuroscience* 1999;93:81–88. [PubMed: 10430472]
84. Gonzalez-Zulueta M, Feldman AB, Klesse LJ, Kalb RG, Dillman JF, Parada LF, Dawson TM, Dawson VL. Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. *Proc Natl Acad Sci U S A* 2000;97:436–441. [PubMed: 10618436]
85. Choi JS, Kim HY, Cha JH, Lee MY. Ischemic preconditioning-induced activation of ERK1/2 in the rat hippocampus. *Neurosci Lett* 2006;409:187–191. [PubMed: 17029782]
86. Wang C, Weihrauch D, Schwabe DA, Bienengraeber M, Warltier DC, Kersten JR, Pratt PF Jr, Pagel PS. Extracellular signal-regulated kinases trigger isoflurane preconditioning concomitant with upregulation of hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in rats. *Anesth Analg* 2006;103:281–288. [PubMed: 16861403]
87. Wang RM, Yang F, Zhang YX. Preconditioning-induced activation of ERK5 is dependent on moderate Ca<sup>2+</sup> influx via NMDA receptors and contributes to ischemic tolerance in the hippocampal CA1 region of rats. *Life Sci* 2006;79:1839–1846. [PubMed: 16859717]
88. Wang RM, Zhang QG, Li CH, Zhang GY. Activation of extracellular signal-regulated kinase 5 may play a neuroprotective role in hippocampal CA3/DG region after cerebral ischemia. *J Neurosci Res* 2005;80:391–399. [PubMed: 15789369]

89. Jia J, Wang X, Li H, Han S, Zu P, Li J. Activations of nPKCepsilon and ERK1/2 were involved in oxygen-glucose deprivation-induced neuroprotection via NMDA receptors in hippocampal slices of mice. *J Neurosurg Anesthesiol* 2007;19:18–24. [PubMed: 17198096]
90. Lange-Asschenfeldt C, Raval AP, Dave KR, Mochly-Rosen D, Sick TJ, Perez-Pinzon MA. Epsilon protein kinase C mediated ischemic tolerance requires activation of the extracellular regulated kinase pathway in the organotypic hippocampal slice. *J Cereb Blood Flow Metab* 2004;24:636–645. [PubMed: 15181371]
91. Raval AP, Dave KR, Mochly-Rosen D, Sick TJ, Perez-Pinzon MA. Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice. *J Neurosci* 2003;23:384–391. [PubMed: 12533598]
92. Raval AP, Dave KR, DeFazio RA, Perez-Pinzon MA. EpsilonPKC phosphorylates the mitochondrial K(+) (ATP) channel during induction of ischemic preconditioning in the rat hippocampus. *Brain Res* 2007;1184:345–353. [PubMed: 17988655]
93. Kurkinen K, Busto R, Goldsteins G, Koistinaho J, Perez-Pinzon MA. Isoform-specific membrane translocation of protein kinase C after ischemic preconditioning. *Neurochem Res* 2001;26:1139–1144. [PubMed: 11700956]
94. Kurkinen K, Keinänen R, Li W, Koistinaho J. Preconditioning with spreading depression activates specifically protein kinase Cdelta. *Neuroreport* 2001;12:269–273. [PubMed: 11209933]
95. Nishimura M, Sugino T, Nozaki K, Takagi Y, Hattori I, Hayashi J, Hashimoto N, Moriguchi T, Nishida E. Activation of p38 kinase in the gerbil hippocampus showing ischemic tolerance. *J Cereb Blood Flow Metab* 2003;23:1052–1059. [PubMed: 12973021]
96. Yin XH, Zhang QG, Miao B, Zhang GY. Neuroprotective effects of preconditioning ischaemia on ischaemic brain injury through inhibition of mixed-lineage kinase 3 via NMDA receptor-mediated Akt1 activation. *J Neurochem* 2005;93:1021–1029. [PubMed: 15857405]
97. Miao B, Yin XH, Pei DS, Zhang QG, Zhang GY. Neuroprotective effects of preconditioning ischemia on ischemic brain injury through down-regulating activation of JNK1/2 via N-methyl-D-aspartate receptor-mediated Akt1 activation. *J Biol Chem* 2005;280:21693–21699. [PubMed: 15797868]
98. Salminen A, Liu PK, Hsu CY. Alteration of transcription factor binding activities in the ischemic rat brain. *Biochem Biophys Res Commun* 1995;212:939–944. [PubMed: 7626134]
99. Walton M, Sirimanne E, Williams C, Gluckman P, Dragunow M. The role of the cyclic AMP-responsive element binding protein (CREB) in hypoxic-ischemic brain damage and repair. *Brain Res Mol Brain Res* 1996;43:21–29. [PubMed: 9037515]
100. Bergeron M, Gidday JM, Yu AY, Semenza GL, Ferriero DM, Sharp FR. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. *Ann Neurol* 2000;48:285–296. [PubMed: 10976634]
101. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. *Oncogene* 2001;20:2438–2452. [PubMed: 11402339]
102. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. *Nat Cell Biol* 2002;4:E131–E136. [PubMed: 11988758]
103. Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB. Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. *Cell Cycle* 2007;6:2633–2639. [PubMed: 17957143]
104. Kiessling M, Stumm G, Xie Y, Herdegen T, Aguzzi A, Bravo R, Gass P. Differential transcription and translation of immediate early genes in the gerbil hippocampus after transient global ischemia. *J Cereb Blood Flow Metab* 1993;13:914–924. [PubMed: 8408317]
105. An G, Lin TN, Liu JS, Xue JJ, He YY, Hsu CY. Expression of c-fos and c-jun family genes after focal cerebral ischemia. *Ann Neurol* 1993;33:457–464. [PubMed: 7684582]
106. Whitfield PC, Williams R, Pickard JD. Delayed induction of JunB precedes CA1 neuronal death after global ischemia in the gerbil. *Brain Res* 1999;818:450–458. [PubMed: 10082831]
107. Yoneda Y, Kuramoto N, Azuma Y, Ogita K, Mitani A, Zhang L, Yanase H, Masuda S, Kataoka K. Possible involvement of activator protein-1 DNA binding in mechanisms underlying ischemic tolerance in the CA1 subfield of gerbil hippocampus. *Neuroscience* 1998;86:79–97. [PubMed: 9692745]

108. Kapinya K, Penzel R, Sommer C, Kiessling M. Temporary changes of the AP-1 transcription factor binding activity in the gerbil hippocampus after transient global ischemia, and ischemic tolerance induction. *Brain Res* 2000;872:282–293. [PubMed: 10924710]
109. Dhodda VK, Sailor KA, Bowen KK, Vemuganti R. Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. *J Neurochem* 2004;89:73–89. [PubMed: 15030391]
110. Sommer C, Gass P, Kiessling M. Selective c-JUN expression in CA1 neurons of the gerbil hippocampus during and after acquisition of an ischemia-tolerant state. *Brain Pathol* 1995;5:135–144. [PubMed: 7670654]
111. Hu BR, Fux CM, Martone ME, Zivin JA, Ellisman MH. Persistent phosphorylation of cyclic AMP responsive element-binding protein and activating transcription factor-2 transcription factors following transient cerebral ischemia in rat brain. *Neuroscience* 1999;89:437–452. [PubMed: 10077326]
112. Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. *Trends Neurosci* 2005;28:436–445. [PubMed: 15982754]
113. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. *Neuron* 2002;35:605–623. [PubMed: 12194863]
114. Mabuchi T, Kitagawa K, Kuwabara K, Takasawa K, Ohtsuki T, Xia Z, Storm D, Yanagihara T, Hori M, Matsumoto M. Phosphorylation of cAMP response element-binding protein in hippocampal neurons as a protective response after exposure to glutamate in vitro and ischemia in vivo. *J Neurosci* 2001;21:9204–9213. [PubMed: 11717354]
115. Lee HT, Chang YC, Wang LY, Wang ST, Huang CC, Ho CJ. cAMP response element-binding protein activation in ligation preconditioning in neonatal brain. *Ann Neurol* 2004;56:611–623. [PubMed: 15470752]
116. Hara T, Hamada J, Yano S, Morioka M, Kai Y, Ushio Y. CREB is required for acquisition of ischemic tolerance in gerbil hippocampal CA1 region. *J Neurochem* 2003;86:805–814. [PubMed: 12887679]
117. Rybnikova E, Gluschenko T, Tulkova E, Churilova A, Jaroshevich O, Baranova K, Samoilov M. Preconditioning induces prolonged expression of transcription factors pCREB and NF-kappa B in the neocortex of rats before and following severe hypobaric hypoxia. *J Neurochem* 2008;106:1450–1458. [PubMed: 18547368]
118. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O<sub>2</sub> tension. *Proc Natl Acad Sci U S A* 1995;92:5510–5514. [PubMed: 7539918]
119. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, Ratan RR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. *J Neurosci* 1999;19:9821–9830. [PubMed: 10559391]
120. Chavez JC, LaManna JC. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1. *J Neurosci* 2002;22:8922–8931. [PubMed: 12388599]
121. Hamrick SE, McQuillen PS, Jiang X, Mu D, Madan A, Ferriero DM. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. *Neurosci Lett* 2005;379:96–100. [PubMed: 15823423]
122. Brown IR. Heat shock proteins and protection of the nervous system. *Ann N Y Acad Sci* 2007;1113:147–158. [PubMed: 17656567]
123. Liu Y, Kato H, Nakata N, Kogure K. Temporal profile of heat shock protein 70 synthesis in ischemic tolerance induced by preconditioning ischemia in rat hippocampus. *Neuroscience* 1993;56:921–927. [PubMed: 8284044]
124. Chen J, Graham SH, Zhu RL, Simon RP. Stress proteins and tolerance to focal cerebral ischemia. *J Cereb Blood Flow Metab* 1996;16:566–577. [PubMed: 8964795]
125. Tanaka S, Kitagawa K, Ohtsuki T, Yagita Y, Takasawa K, Hori M, Matsumoto M. Synergistic induction of HSP40 and HSC70 in the mouse hippocampal neurons after cerebral ischemia and ischemic tolerance in gerbil hippocampus. *J Neurosci Res* 2002;67:37–47. [PubMed: 11754079]

126. Hayashi T, Saito A, Okuno S, Ferrand-Drake M, Chan PH. Induction of GRP78 by ischemic preconditioning reduces endoplasmic reticulum stress and prevents delayed neuronal cell death. *J Cereb Blood Flow Metab* 2003;23:949–961. [PubMed: 12902839]
127. Yagita Y, Kitagawa K, Ohtsuki T, Tanaka S, Hori M, Matsumoto M. Induction of the HSP110/105 family in the rat hippocampus in cerebral ischemia and ischemic tolerance. *J Cereb Blood Flow Metab* 2001;21:811–819. [PubMed: 11435793]
128. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. *J Neuroimmunol* 2007;184:53–68. [PubMed: 17188755]
129. Benarroch EE. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. *Mayo Clin Proc* 2005;80:1326–1338. [PubMed: 16212146]
130. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. *Glia* 2001;50:427–434. [PubMed: 15846805]
131. Dong Y, Benveniste EN. Immune function of astrocytes. *Glia* 2001;36:180–190. [PubMed: 11596126]
132. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. *Curr Med Chem* 2007;14:1189–1197. [PubMed: 17504139]
133. Kim SU, de Vellis J. Microglia in health and disease. *J Neurosci Res* 2005;81:302–313. [PubMed: 15954124]
134. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. *Proc Natl Acad Sci U S A* 1998;95:15769–15774. [PubMed: 9861045]
135. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. *Proc Natl Acad Sci U S A* 1999;96:13496–13500. [PubMed: 10557349]
136. Watanabe H, Abe H, Takeuchi S, Tanaka R. Protective effect of microglial conditioning medium on neuronal damage induced by glutamate. *Neurosci Lett* 2000;289:53–66. [PubMed: 10899407]
137. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. *Genes Dev* 2000;14:2919–2937. [PubMed: 11114882]
138. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci* 2003;4:299–309. [PubMed: 12671646]
139. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem* 2003;72:609–642. [PubMed: 12676795]
140. Lindvall O, Ernfors P, Bengzon J, Kokaia Z, Smith ML, Siesjo BK, Persson H. Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma. *Proc Natl Acad Sci U S A* 1992;89:648–652. [PubMed: 1731336]
141. Merlio JP, Ernfors P, Kokaia Z, Middlemas DS, Bengzon J, Kokaia M, Smith ML, Siesjo BK, Hunter T, Lindvall O. Increased production of the TrkB protein tyrosine kinase receptor after brain insults. *Neuron* 1993;10:151–164. [PubMed: 8439408]
142. Takeda A, Onodera H, Sugimoto A, Kogure K, Obinata M, Shibahara S. Coordinated expression of messenger RNAs for nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 in the rat hippocampus following transient forebrain ischemia. *Neuroscience* 1993;55:23–31. [PubMed: 8350988]
143. Beck T, Lindholm D, Castren E, Wree A. Brain-derived neurotrophic factor protects against ischemic cell damage in rat hippocampus. *J Cereb Blood Flow Metab* 1994;14:689–692. [PubMed: 8014217]
144. Shigeno T, Mima T, Takakura K, Graham DI, Kato G, Hashimoto Y, Furukawa S. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. *J Neurosci* 1991;11:2914–2919. [PubMed: 1880556]
145. Tanaka K, Tsukahara T, Hashimoto N, Ogata N, Yonekawa Y, Kimura T, Taniguchi T. Effect of nerve growth factor on delayed neuronal death after cerebral ischaemia. *Acta Neurochir (Wien)* 1994;129:64–71. [PubMed: 7998499]
146. Marini AM, Jiang X, Wu X, Pan H, Guo Z, Mattson MP, Blondeau N, Novelli A, Lipsky RH. Preconditioning and neurotrophins: a model for brain adaptation to seizures, ischemia and other stressful stimuli. *Amino Acids* 2007;32:299–304. [PubMed: 16998712]

147. Truettner J, Busto R, Zhao W, Ginsberg MD, Perez-Pinzon MA. Effect of ischemic preconditioning on the expression of putative neuroprotective genes in the rat brain. *Brain Res Mol Brain Res* 2002;103:106–115. [PubMed: 12106696]
148. Pera J, Zawadzka M, Kaminska B, Szczudlik A. Neurotrophic factor expression after focal brain ischemia preceded by different preconditioning strategies. *Cerebrovasc Dis* 2005;19:247–252. [PubMed: 15731555]
149. Lee TH, Yang JT, Ko YS, Kato H, Itoyama Y, Kogure K. Influence of ischemic preconditioning on levels of nerve growth factor, brain-derived neurotrophic factor and their high-affinity receptors in hippocampus following forebrain ischemia. *Brain Res* 2008;1187:1–11. [PubMed: 18036511]
150. Stenzel-Poore MP, Stevens SL, Simon RP. Genomics of preconditioning. *Stroke* 2004;35:2683–2686. [PubMed: 15459430]
151. Meller R, Cameron JA, Torrey DJ, Clayton CE, Ordonez AN, Henshall DC, Minami M, Schindler CK, Saugstad JA, Simon RP. Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons. *J Biol Chem* 2006;281:7429–7436. [PubMed: 16431916]
152. Meller R, Minami M, Cameron JA, Impey S, Chen D, Lan JQ, Henshall DC, Simon RP. CREB-mediated Bcl-2 protein expression after ischemic preconditioning. *J Cereb Blood Flow Metab* 2005;25:234–246. [PubMed: 15647742]
153. Atkinson TJ. Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness? *Int Rev Immunol* 2008;27:255–281. [PubMed: 18574739]
154. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, Lessov NS, Simon RP, Stenzel-Poore MP. Toll-like receptor 9: a new target of ischemic preconditioning in the brain. *J Cereb Blood Flow Metab* 2008;28:1040–1047. [PubMed: 18183029]
155. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. *Neuroscience*. 2008